Jenesis Innovative Research Awards™
This annual award program is designed to support independent research to expand the scientific knowledge base and ultimately improve healthcare delivery in disciplines related to the pulmonary hypertension spectrum of diseases through the support of targeted research proposals by junior investigators.
Grant submissions are reviewed by an independent research committee of senior investigators with experience in outcomes, clinical, or preclinical research. Each award recipient may be eligible to receive up to $100,000.
Available grants include:
Jenesis Outcomes Award™
Exploring the science of clinical or patient-reported outcomes research.
Jenesis Clinical Award™
Exploring treatment of unmet populations or novel treatment approaches
Jenesis Preclinical Award™
Exploring the mechanistic benefits of prostacyclin-class therapy through translational research
Eligibility requirements for grant submission include:
- Junior faculty researchers within 5 years since first faculty appointment at the time of application
- Currently engaged in outcomes, translational, and/or clinical research related to the pulmonary hypertension spectrum of diseases
- Adequate mentorship and institutional commitment
- Final report or manuscript of results required
For additional information, please email UTjenesisawards@contacthmc.com.
To submit an application, please visit UTJenesisAwards.com.
Martine and Bina Rothblatt founded United Therapeutics when their daughter Jenesis was diagnosed with PAH as a young girl. Faced with a stunning lack of information, support, and treatment options, they became committed to providing better therapies and eventually a cure for this disease. Jenesis and her story remain the inspiration behind United Therapeutics and the motivation for the Jenesis Innovative Research Awards, designed to award junior investigators dedicated to medical advancement for pulmonary hypertension through independent clinical, preclinical, and outcomes-based research.